Abstract
AbstractIntroductionPharmacotherapy‐related prevention of cardiac allograft vasculopathy, optimal immunosuppression regimens, and metabolic management are essential for promotion of graft survival in heart transplant recipients.MethodsFollowing the addition of an ambulatory clinical pharmacist to the heart transplant team at an academic medical center in January 2018, we sought to assess the impact of pharmacist integration on pharmacotherapy‐related clinical outcomes including goal blood pressure, diabetes control, appropriate statin and aspirin utilization, tacrolimus variability, and patient and graft outcomes at 1 year postheart transplant via a retrospective pre‐post analysis.ResultsFifty‐nine heart transplant recipients were included. At 1 year, the pharmacist cohort had a higher percentage of heart transplant recipients at goal blood pressure (93.1 vs 71.4%, P = .03), on a statin (96.7 vs 67.9%, P = .004), and with fewer 1 year hospital readmissions (55 vs 28, P = .03); no significant differences in HbA1c, aspirin use, tacrolimus level variability, or patient and graft survival were observed.DiscussionThis analysis suggests that the integration of a pharmacist into the routine ambulatory care of heart transplant recipients is associated with improvement in several pharmacotherapy‐related clinical outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
